Table 1.

Baseline characteristics in male and female patients

	SOX					CS
	Male (n = 257)		Female (n = 81)		P  a	Male (n = 243)		Female (n = 92)		P  a
	n	%	n	%		n	%	n	%
Age
<65	111	43.2	42	51.9	.201	109	44.9	53	57.6	.038
≥65	146	56.8	39	48.1		134	55.1	39	42.4
ECOG performance status
0	183	71.2	56	63.5	.414	177	72.8	59	64.1	.109
1	72	28.0	23	28.4		62	25.5	33	35.9
2	2	0.8	2	2.5		4	1.6	0	0
Unresectable	207	80.5	71	87.7	.182	199	81.9	78	84.8	.628
Recurrent	50	19.5	10	12.3		44	18.1	14	15.2
Adjuvant chemotherapy (+)	24	9.3	7	8.6		20	8.2	9	9.8
Adjuvant chemotherapy (‐)	26	10.1	3	3.7		24	9.9	5	5.4
Tumor histology
Differentiated type	125	48.6	29	35.8	.055	119	49.0	29	31.5	.005
Undifferentiated type	132	51.4	52	64.2		124	51.0	63	68.5
Primary tumor
‐	66	25.7	13	16.0	.097	62	25.5	17	18.5	.196
+	191	74.3	68	84.0		181	74.5	75	81.5
No. of metastatic sites
1	87	33.9	22	27.2	.377	78	32.1	26	28.3	.455
2	105	40.9	33	40.7		107	44.0	36	39.1
≥3	59	23.0	24	29.6		57	23.5	27	29.3
Metastatic site b
Liver	104	40.5	22	27.2		101	41.6	30	32.6
Lung	32	12.5	5	6.2		27	11.1	8	8.7
Lymph node	225	87.5	74	91.4		214	88.1	79	85.9
Peritoneum	45	17.5	21	25.9		44	18.1	21	22.8

Abbreviations: CS, cisplatin plus S‐1; ECOG, Eastern Cooperative Oncology Group; SOX, S‐1 plus oxaliplatin.

^aFisher's exact test; comparing proportion of each characteristic.

^bPatients can be included in more than one category.